VIR Vir Biotechnology
- 9.610
- -0.160-1.64%
Vir Biotechnology News
Analysts Conflicted on These Healthcare Names: Vir Biotechnology (VIR) and Moderna (MRNA)
Vir Biotechnology Price Target Maintained With a $110.00/Share by HC Wainwright & Co.
Vir Biotechnology's Promising Hepatitis Programs and Strategic FDA Alignment Justify Buy Rating
Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $26
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $10 to $19
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $10 to $19
Vir Biotechnology Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Corvus Pharmaceuticals (CRVS), Vir Biotechnology (VIR) and Cooper Co (COO)
Vir Biotechnology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Hold Rating, Maintains Target Price $15
Vir Biotechnology Analyst Ratings
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $13 to $28
Analysts Offer Insights on Healthcare Companies: Passage Bio (PASG), Regeneron (REGN) and Vir Biotechnology (VIR)
Analysts Are Bullish on Top Healthcare Stocks: Neurocrine (NBIX), Vir Biotechnology (VIR)
Strategic Restructuring and Portfolio Diversification Solidify Buy Rating for Vir Biotechnology
Barclays Reaffirms Their Buy Rating on Vir Biotechnology (VIR)
Vir Biotechnology (VIR) Receives a Buy From TD Cowen
Vir Biotechnology Lowers FY24 Operating Expense Guidance >VIR
Vir Biotechnology Analyst Ratings
Analysis
Price Target
No Data
No Data